On September 14, 2024, the Clinical Research Organization Branch (CRO Branch) of China Pharmaceutical Quality Management Association successfully held its 3rd meeting of 2024 in Wuhan. Hosted by Wuhan Hongren Biomedical Co., Ltd., the meeting gathered nearly 60 representatives from 36 member units.
Highlights of the Meeting
Chaired by Secretary-General Wang Wei, the meeting first reviewed the basic information, recent activities, and financial status of the Branch. Subsequently, upon the unanimous vote of the participating representatives, four units—Shanghai Biaodu Bio-Tech Co., Ltd., Wuhan Bokang Technology Co., Ltd., Hefei Anshuo Pharmaceutical Technology Co., Ltd., and Wuhan Boruiheng Pharmaceutical Technology Co., Ltd.—officially became member units of the Branch.
Dr. Jiang Hongliang, Chairman of the Board of the host unit Wuhan Hongren Biomedical Co., Ltd., extended a warm welcome to the peers and experts coming from afar at the opening ceremony and expressed gratitude for their long-term cooperation and support. In his speech, Dr. Jiang emphasized the importance of technology and brand value, and called for greater emphasis on quality and service while maintaining reasonable prices.
Dr. Ye Xiaoping, Chairman of the CRO Branch and Chairman of the Board of Hangzhou Tigermed Consulting Co., Ltd., pointed out in his speech that facing the challenges and opportunities in the current economic environment, enterprises should maintain a positive attitude, focus on core businesses, control costs, maintain profitability, and maintain good communication with investors and the Association. He also stressed the significance of the Branch’s regular meetings and exchanges for promoting cooperation and progress within the industry.
Wu Jie, Chairman of the Board of Novasyte (Beijing) Pharmaceutical Technology Co., Ltd., shared his company’s strategies for responding to market competition, encouraging the participants to maintain a positive mindset and pursue innovation and cooperation. He particularly highlighted the importance of the entrepreneurial spirit and expressed expectation that the participants would jointly discuss issues related to enterprise development to drive the healthy growth of the entire industry.
Representatives from multiple member units conducted sharing and discussions around the theme of “Reflections and Discussions on Industry Development Under Adversity”. Throughout the discussion, the participants engaged in enthusiastic exchanges, collectively expressing their firm attitude in the face of industry challenges and their confidence in the future development of the industry. They agreed that during difficult times, enterprises should focus more on their core strengths, seek innovation and cooperation, and achieve sustainable development. By sharing experiences and strategies, the participants enhanced the cohesion within the industry and their determination to jointly address challenges.
Active Participation of Hippocrates Health
Dr. Xiao Liang, Founder of Hippocrates Health, attended the meeting as the company’s representative, actively participating in discussions and jointly exploring new opportunities for industry development. During the meeting, Dr. Xiao Liang shared the latest progress of Hippocrates Health in the application of intelligent technologies, emphasizing the importance of AI technology in improving the efficiency and quality of clinical research. He pointed out that in the face of industry challenges, enterprises should focus on their core advantages and leverage technological innovation to promote sustainable development.
Concluding Remarks
At the end of the meeting, Secretary-General Wang Wei delivered a key summary speech. He proposed that under the backdrop of the overall grim economic situation, the CRO industry needs to strengthen internal management, improve operational efficiency, effectively control costs, and ensure the provision of high-quality services. He also suggested that member enterprises should enhance cooperation and communication, share resources and experiences, improve cooperation efficiency, and consider selective cooperation in business collaborations to avoid unnecessary excessive competition and price wars.
About Hippocrates
Hippocrates Health Technology Co., Ltd. is a high-tech enterprise dedicated to providing digital solutions for the life and health industry. Relying on its profound technological accumulation and extensive practical experience, the company continuously explores and innovates to provide efficient and compliant digital solutions for the pharmaceutical industry. Hippocrates Health always pays attention to industry trends, actively participates in various industry conferences, and is committed to promoting the sustainable development of the pharmaceutical industry.
Closing
The meeting concluded successfully amid enthusiastic discussions and in-depth exchanges. The participants spoke highly of the meeting content and expressed expectations for future exchanges and cooperation. The next meeting is scheduled to be held from December 11 to 12.
